Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings
October 11 2016 - 8:00AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical
company developing CODIT™ (Characterized Oral
Desensitization ImmunoTherapy) treatments for
life-threatening food allergies, today announced that it will
present Phase 2 clinical data on AR101, its investigational
biologic oral immunotherapy for desensitization of patients with
peanut allergy, and host corporate forums at:
- The European Academy of Allergy and
Clinical Immunology’s 4th Food Allergy and Anaphylaxis Meeting
(FAAM), October 13-15, 2016, in Rome
- The 2016 Annual Scientific Meeting of
the American College of Asthma, Allergy & Immunology (ACAAI),
November 10-14, 2016, in San Francisco
Details for Aimmune Presentations at FAAM, October 13-15,
2016, in Rome
Poster Presentation
- #PP145: “The Stability of Peanut
Allergens in AR101, an Oral Immunotherapeutic for the Treatment of
Peanut Allergy, in Two Representative Food Matrices” (Presenting
author: R. Simon) on Saturday, October 15, 11:30 AM – 1:00 PM, in
Poster Session 4 (Food Allergens) in the Poster Area (La Piazzetta
B & C).
Corporate Forum
Aimmune will host an Industry Satellite Symposium titled “Peanut
Allergy Oral Immunotherapy: Exploring the Needs of Peanut-Allergic
Patients and Their Families” on Friday, October 14, 12:45-1:45 PM,
at the Plenary Hall (Medici Visconti), and will feature:
- George Du Toit, M.B., B.Ch., Guy’s and
St Thomas’ Hospital, London, and Evelina Children’s Hospital,
London, Moderator
- Audrey Dunn Galvin, Ph.D., University
College Cork, Ireland, “Defining the Unmet Needs of Peanut-Allergic
Patients and Their Families”
- Andrea Vereda, M.D., Ph.D., Aimmune
Therapeutics, “Targeting the Growing, Unmet Need for Peanut Allergy
Treatment: Aimmune’s Clinical Development Approach”
Details for Aimmune Presentations at ACAAI, November 10-14,
2016, in San Francisco
Oral Presentations
- #O055: “Immunologic Effects of AR101
During Characterized Oral Desensitization Immunotherapy (CODIT) for
Peanut Allergy” (Presenting author: E. Kim) on Monday, November
14.
- #O056 “Baseline Peanut-Specific IgE
Potentially Predicts Up-Dose Completion and Treatment Response with
AR101 in CODIT” (Presenting author: J. Wang) on Monday, November
14.
Corporate Forum
Aimmune will host a Corporate Forum titled “Peanut Oral
Immunotherapy: Thresholds of Eliciting Dose, Clinical and Immune
Response from AR101 Phase 2 Clinical Trials, and Treatment
Optimization Through Early Intervention” on Friday, November
11.
Additional details will be available closer to the time of the
meeting.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for
life-threatening food allergies. The company’s Characterized
Oral Desensitization ImmunoTherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized biologic product candidates with gradual,
controlled up-dosing protocols to obtain clinically meaningful
desensitization to food allergens. Aimmune’s first CODIT product,
AR101 for the treatment of peanut allergy, has received the FDA’s
Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials. For more information, please
see www.aimmune.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161011005658/en/
Aimmune TherapeuticsInvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2024 to May 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From May 2023 to May 2024